{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:10:58Z","timestamp":1763017858830},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie Spain","award":["ACA-SPAI-08-16"],"award-info":[{"award-number":["ACA-SPAI-08-16"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0195068","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T17:39:20Z","timestamp":1523554760000},"page":"e0195068","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir\/ritonavir monotherapy: A randomized clinical trial"],"prefix":"10.1371","volume":"13","author":[{"given":"Juan","family":"Pasquau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luisa","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Romero-Palacios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Vergas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Sanjoaqu\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez-Quero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koldo","family":"Aguirrebengoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Orihuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkaitz","family":"Imaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"R\u00edos-Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Carmen","family":"Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Garc\u00eda-Merc\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"de los Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha Elizabeth","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coral","family":"Garc\u00eda-Vallecillos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of The QoLKAMON STUDY GROUP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"MA Thompson","year":"2012","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-94-007-2869-1_16","article-title":"Iatrogenic mitochondriopathies: a recent lesson from nucleoside\/nucleotide reverse transcriptase inhibitors","volume":"942","author":"GP Leung","year":"2012","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/339041","article-title":"Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature","volume":"34","author":"V Falco","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-0034-1372345","article-title":"Central nervous system HIV infection in &quot;less-drug regimen&quot; antiretroviral therapy simplification strategies","volume":"34","author":"F Ferretti","year":"2014","journal-title":"Semin Neurol"},{"key":"ref5","unstructured":"Paton N SW, Arenas-Pinto A, Dunn D for the PIVOT Trial Team, editor Randomised Controlled Trial of a PI Monotherapy Switch Strategy for Long-term HIV Management (The PIVOT Trial). 21st Conference on Retroviruses and Opportunistic Infections (CROI) Paper number 550 LB; 2014 3\u20136 March; BOSTON."},{"issue":"26","key":"ref6","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"S Walmsley","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/380509","article-title":"Incidence of resistance in a double-blind study comparing lopinavir\/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine","volume":"189","author":"DJ Kempf","year":"2004","journal-title":"J Infect Dis"},{"issue":"5","key":"ref8","first-page":"1023","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review","volume":"4","author":"A Chandwani","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.antiviral.2009.07.006","article-title":"Molecular basis of human immunodeficiency virus drug resistance: an update","volume":"85","author":"L Menendez-Arias","year":"2010","journal-title":"Antiviral Res"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1128\/AAC.01643-08","article-title":"Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy","volume":"53","author":"C Delaugerre","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/QAI.0b013e3181a56de5","article-title":"Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis","volume":"51","author":"JR Arribas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref12","first-page":"769627","article-title":"Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir\/r-Containing Antiretroviral Therapy in South Africa","volume":"2011","author":"CL Wallis","year":"2011","journal-title":"AIDS Res Treat"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/QCO.0b013e3283422cdf","article-title":"Protease inhibitor monotherapy","volume":"24","author":"I Perez-Valero","year":"2011","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/jac\/dkq327","article-title":"Lopinavir\/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial","volume":"65","author":"JL Meynard","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/589622","article-title":"A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy","volume":"198","author":"DW Cameron","year":"2008","journal-title":"J Infect Dis"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jac\/dkm198","article-title":"Lopinavir\/ritonavir monotherapy as a simplification strategy in routine clinical practice","volume":"60","author":"J Molto","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"e23726","DOI":"10.1371\/journal.pone.0023726","article-title":"Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV\/r maintenance therapy in HIV patients on the 1 PI-based regimen","volume":"6","author":"P Cahn","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1310\/hct1006-368","article-title":"Monotherapy with Lopinavir\/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study)","volume":"10","author":"EP Nunes","year":"2009","journal-title":"HIV Clin Trials"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jac\/dkq084","article-title":"Impact of 48 week lopinavir\/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial","volume":"65","author":"V Avettand-Fenoel","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/jac\/dkn103","article-title":"Long-term (4 years) efficacy of lopinavir\/ritonavir monotherapy for maintenance of HIV suppression","volume":"61","author":"F Pulido","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"ref21","unstructured":"Berenguer J, Pedrol PD, Polo R. Documento de consenso de Gesida\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana 2002. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.gesida-seimc.org\/pcientifica\/fuentes\/DcyRc\/gesidadcyrc2012-Documentoconsenso-TAR-adulto-verordenador.pdf\" xlink:type=\"simple\">http:\/\/www.gesida-seimc.org\/pcientifica\/fuentes\/DcyRc\/gesidadcyrc2012-Documentoconsenso-TAR-adulto-verordenador.pdf<\/ext-link>."},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"NI Paton","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"ref23","first-page":"490","article-title":"Pharmacoeconomic analysis of a maintenance strategy with lopinavir\/ritonavir monotherapy in HIV-infected patients","volume":"24","author":"I Escobar","year":"2006","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"6","key":"ref24","first-page":"317","article-title":"Simplification of antiretroviral therapy: a good choice for our patients and the sustainability of our health care system","volume":"35","author":"L Gonzalez Rivas","year":"2011","journal-title":"Farm Hosp"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/11598380-000000000-00000","article-title":"Budget impact analysis of switching to darunavir\/ritonavir monotherapy for HIV-infected people in Spain","volume":"10","author":"J Pasquau","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-6405-10-3","article-title":"Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting","volume":"10","author":"JR Arribas","year":"2013","journal-title":"AIDS Res Ther"},{"issue":"2","key":"ref27","first-page":"188","article-title":"Algorithm AS 183: An efficient and portable pseudo-random number generator","volume":"31","author":"BA Wichmann","year":"1982","journal-title":"Journal of the Royal Statistical Society Series C (Applied Statistics)"},{"issue":"2","key":"ref28","first-page":"198","article-title":"Remark AS R58: a remark on algorithm AS 183. An efficient and portable pseudo-random number generator","volume":"34","author":"AI McLeod","year":"1985","journal-title":"Journal of the Royal Statistical Society Series C (Applied Statistics)"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1477-7525-11-42","article-title":"Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies","volume":"11","author":"AW Wu","year":"2013","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study","volume":"16","author":"H Knobel","year":"2002","journal-title":"AIDS"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1310\/JFXH-G3X2-EYM6-D6UG","article-title":"Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale","volume":"5","author":"TP Giordano","year":"2004","journal-title":"HIV Clin Trials"},{"issue":"10","key":"ref32","first-page":"586","article-title":"Validation of a questionnaire to estimate satisfaction with antiretroviral treatment: CESTA questionnaire","volume":"23","author":"E Condes","year":"2005","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"A Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00704430","article-title":"Changes in quality of life among persons with HIV infection","volume":"1","author":"DP Lubeck","year":"1992","journal-title":"Qual Life Res"},{"issue":"10","key":"ref35","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S2352-3018(15)00176-9","article-title":"Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial","volume":"2","author":"NI Paton","year":"2015","journal-title":"Lancet HIV"},{"issue":"18","key":"ref36","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1097\/QAD.0b013e32801189f6","article-title":"The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir\/ritonavir alone","volume":"20","author":"JE McKinnon","year":"2006","journal-title":"AIDS"},{"issue":"3","key":"ref37","first-page":"127","article-title":"Boosted protease inhibitor monotherapy. What have we learnt after seven years of research?","volume":"12","author":"F Pulido","year":"2010","journal-title":"AIDS Rev"},{"issue":"Suppl 16","key":"ref38","first-page":"24","article-title":"Lopinavir\/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice","volume":"26","author":"J Molto","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"Suppl 16","key":"ref39","first-page":"21","article-title":"Lopinavir\/ritonavir monotherapy. Possible indications","volume":"26","author":"J Lopez Aldeguer","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"Suppl 16","key":"ref40","first-page":"12","article-title":"Lopinavir\/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection","volume":"26","author":"F Pulido Ortega","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"8","key":"ref41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/157016212803901419","article-title":"Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection","volume":"10","author":"L Calza","year":"2012","journal-title":"Curr HIV Res"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/135965350801300405","article-title":"Effect of lopinavir\/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial","volume":"13","author":"B Spire","year":"2008","journal-title":"Antivir Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0195068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T05:45:42Z","timestamp":1660887942000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0195068"}},"subtitle":[],"editor":[{"given":"Alan","family":"Winston","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0195068","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2018,4,12]]}}}